Melodie Thomas

Suggest Changes
  • Citations Per Year
Learn More
BACKGROUND Patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients.(More)
PURPOSE This phase II study was designed to determine the feasibility, toxicity, and therapeutic efficacy of a novel outpatient combined-modality preoperative regimen in patients with localized(More)
  • 1